Tango Therapeutics (NASDAQ: TNGX) announced inducement equity awards effective May 1, 2026 under its 2023 Inducement Plan.
The Compensation Committee granted Mr. Matthew Gall a non‑qualified option for 240,000 shares and 40,000 RSUs, and a new employee an option for 199,650 shares and 33,250 RSUs, at an exercise price of $20.98 per share. Options have a 10‑year term; option vesting: 25% at year one then monthly over three years; RSUs vest in three approximately equal annual installments in May 2027–2029. Awards are subject to the 2023 Inducement Plan and award agreements.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – TNGX
+6.56%
34 alerts
+6.56%Session close to close
+10.5%Peak in 9 hr 25 min
$3.36BMarket Cap
0.3xRel. Volume
In the May 5 session, TNGX gained 6.56%, reflecting a notable positive market reaction.
Argus tracked a peak move of +10.5% during that session.
Our momentum scanner triggered 34 alerts that day, indicating elevated trading interest and price volatility.
The stock moved +6.6% in the session following this news. A strong positive reaction aligns with Tan...
Analysis
The stock moved +6.6% in the session following this news. A strong positive reaction aligns with Tango’s history of favorable responses to equity and leadership updates, as seen after news on Apr 15, 2026 and earnings on Mar 5, 2026. However, today’s grants add to existing insider equity overhang and sit alongside an effective resale registration covering 1,732,101 shares. High prior insider selling activity could limit follow‑through if buying interest fades or profit‑taking resumes.
Key Figures
CFO option grant:240,000 optionsCFO RSU grant:40,000 RSUsNew hire equity:199,650 options & 33,250 RSUs+5 more
8 metrics
CFO option grant240,000 optionsNon-qualified stock options to CFO under 2023 Inducement Plan
CFO RSU grant40,000 RSUsInducement RSUs to CFO vesting over three years
New hire equity199,650 options & 33,250 RSUsInducement awards to new employee under 2023 Inducement Plan
Option exercise price$20.98 per shareExercise price equal to May 1, 2026 closing price
Cash balance$343.1 millionCash as of Dec 31, 2025 with runway into 2028
Financing$225 millionFinancing completed in October 2025 highlighted in DEF 14A
Vopimetostat ORR27% objective response ratePhase 1/2 monotherapy data in MTAP-deleted cancers
Median PFS6.4 monthsMedian progression-free survival across 94 tumor-evaluable patients
CEO scheduled for fireside chat at Guggenheim biotech summit.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Larger positive moves have followed strategic and financial updates, while routine announcements such as conference participation or inducement grants have seen smaller, mixed reactions.
Recent Company History
Over recent months, Tango’s news flow highlighted financing strength, pipeline progress, and leadership changes. On Mar 5, 2026, Q4 and full‑year 2025 results plus business highlights coincided with a 36.28% gain, supported by $343.1 million cash and plans for a pivotal vopimetostat study. Leadership and equity-award changes around Apr 15, 2026 also saw a positive reaction. In contrast, routine items like inducement grants and earnings date or conference notices produced modest, mixed moves, framing today’s inducement awards as part of ongoing compensation practices.
"granted (i) a non-qualified stock option to purchase an aggregate of 240,000 shares"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
restricted stock unitsfinancial
"shares of its common stock and 40,000 restricted stock units (RSUs) to Matthew Gall"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
rsusfinancial
"shares of its common stock and 40,000 restricted stock units (RSUs) to Matthew Gall"
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
nasdaq listing rule 5635(c)(4)regulatory
"under Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
inducement planfinancial
"under Tango Therapeutics' 2023 Inducement Plan."
An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.
BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that effective May 1, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors granted (i) a non-qualified stock option to purchase an aggregate of 240,000 shares of its common stock and 40,000 restricted stock units (RSUs) to Matthew Gall, the Company’s Chief Financial Officer and (ii) a non-qualified stock option to purchase an aggregate of 199,650 shares of its common stock and 33,250 RSUs to a new employee, under Tango Therapeutics' 2023 Inducement Plan.
The Tango Therapeutics 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to such individual's entering into employment with Tango Therapeutics, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
The options granted to Mr. Gall and the other employee have an exercise price of $20.98 per share, which is equal to the closing price of Tango Therapeutics' common stock on May 1, 2026. The stock options have a 10-year term and will vest over four years, with 25% of the options vesting on the first anniversary of the respective employee’s first date of employment and the remaining 75% of the options vesting in equal monthly installments over the three years thereafter, subject to the respective employee’s continued employment on each vesting date. The RSUs granted to Mr. Gall and the other employee will vest over three years, in three approximately equal installments on or about May 10, 2027, May 10, 2028 and May 9, 2029, subject to the respective employee’s continued employment on each vesting date. The options and RSUs are subject to the terms and conditions of Tango Therapeutics' 2023 Inducement Plan, which was approved in February 2023, and the terms and conditions of the stock option and RSU agreements covering the grant.
AboutTangoTherapeutics
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com.
What equity awards did Tango Therapeutics (TNGX) grant on May 1, 2026?
Tango granted options and RSUs to two employees, including CFO Matthew Gall. According to the company, grants include 240,000-option/40,000-RSU for the CFO and 199,650-option/33,250-RSU for a new employee.
What is the exercise price and term of the Tango Therapeutics (TNGX) options granted May 1, 2026?
The options carry an exercise price of $20.98 per share and a 10‑year term. According to the company, $20.98 equals the closing price of Tango common stock on May 1, 2026.
How do the stock option vesting schedules for TNGX inducement grants work?
Options vest over four years with 25% vesting after one year and the remaining 75% monthly over three years. According to the company, vesting is subject to continued employment on each vesting date.
When will the RSUs from Tango Therapeutics' May 2026 inducement grants vest?
The RSUs vest over three years in approximately equal installments on or about May 10, 2027; May 10, 2028; and May 9, 2029. According to the company, vesting is subject to continued employment.
Under which plan were the May 1, 2026 inducement awards to TNGX employees granted?
Awards were granted under the 2023 Inducement Plan pursuant to Nasdaq Rule 5635(c)(4). According to the company, that plan is used exclusively for inducement grants tied to new employment.
